JP6267715B2 - ミリセチンを有効成分として含む運動遂行能力の増強用または疲労回復用の組成物 - Google Patents
ミリセチンを有効成分として含む運動遂行能力の増強用または疲労回復用の組成物 Download PDFInfo
- Publication number
- JP6267715B2 JP6267715B2 JP2015536673A JP2015536673A JP6267715B2 JP 6267715 B2 JP6267715 B2 JP 6267715B2 JP 2015536673 A JP2015536673 A JP 2015536673A JP 2015536673 A JP2015536673 A JP 2015536673A JP 6267715 B2 JP6267715 B2 JP 6267715B2
- Authority
- JP
- Japan
- Prior art keywords
- myricetin
- composition
- exercise performance
- enhancement
- exercise
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 title claims description 79
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 title claims description 78
- 235000007743 myricetin Nutrition 0.000 title claims description 78
- 229940116852 myricetin Drugs 0.000 title claims description 78
- 239000000203 mixture Substances 0.000 title claims description 24
- 239000004480 active ingredient Substances 0.000 title claims description 14
- 230000002708 enhancing effect Effects 0.000 title claims description 14
- 230000014509 gene expression Effects 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 108010016592 Nuclear Respiratory Factor 1 Proteins 0.000 claims description 15
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 102000000524 Nuclear Respiratory Factor 1 Human genes 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 11
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 6
- 235000009134 Myrica cerifera Nutrition 0.000 claims description 5
- 244000061457 Solanum nigrum Species 0.000 claims description 5
- 230000002438 mitochondrial effect Effects 0.000 claims description 5
- 241000208422 Rhododendron Species 0.000 claims description 4
- 244000042324 Trifolium repens Species 0.000 claims description 4
- 230000004783 oxidative metabolism Effects 0.000 claims description 3
- 241000758791 Juglandaceae Species 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 235000020234 walnut Nutrition 0.000 claims description 2
- 102000003921 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Human genes 0.000 claims 2
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 241000025852 Eremochloa ophiuroides Species 0.000 claims 1
- 244000044283 Toxicodendron succedaneum Species 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000037406 food intake Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000003579 anti-obesity Effects 0.000 description 9
- 230000003712 anti-aging effect Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 6
- 230000004898 mitochondrial function Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 230000036362 sensorimotor function Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- -1 glycerin fatty acid ester Chemical class 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000013540 Trifolium repens var repens Nutrition 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037147 athletic performance Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008437 mitochondrial biogenesis Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000723382 Corylus Species 0.000 description 2
- 235000007466 Corylus avellana Nutrition 0.000 description 2
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- AGBCLJAHARWNLA-UHFFFAOYSA-N (20R)-ginsenoside Rg2 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C3C(C)(C)C(O)CCC3(C)C3C(C4(CCC(C4C(O)C3)C(C)(O)CCC=C(C)C)C)(C)C2)OC(CO)C(O)C1O AGBCLJAHARWNLA-UHFFFAOYSA-N 0.000 description 1
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102000009878 3-Hydroxysteroid Dehydrogenases Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000383638 Allium nigrum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 description 1
- 101000744001 Ruminococcus gnavus (strain ATCC 29149 / VPI C7-9) 3beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical compound O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 description 1
- 230000036421 sense of balance Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000004320 sodium erythorbate Substances 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
1−1.ミリセチン投与群及び陰性対照群の用意
8週齢のICRマウス10匹を(株)コアテック(KOATECH、韓国)から購入して、1週間の予備飼育した後、5匹ずつ2つのグループに分けた。
一つ目のグループは、リン酸緩衝食塩水を投与して陰性対照群として設定して、二つ目のグループは、ミリセチンを50mg/kgの濃度で2週間毎日経口投与した。
ミリセチンの持久性の運動遂行能力の変化を測定するために、陰性対照群とミリセチン投与群の動物にトレッドミル運動(Panlab&Harvard、Spain)をさせた。
2−1.ミリセチン投与群及び陰性対照群の用意
ミリセチンによるマウスの持久性の運動遂行能力の強化の効果を測定するために、生後8週になった体重30±5gのICR系列10匹を用いた。実施例1と同様に実験動物を2つのグループに分けた後、一つ目のグループを陰性対照群と設定して、二つ目のグループは、ミリセチンを50mg/kgの濃度で2週間毎日経口投与した。
ミリセチンの筋肉最高力の変化を測定するために、対照群とミリセチン投与群の動物に握力テスト(Bioseb、France)を実施した。
3−1.ミリセチン投与群及び陰性対照群の用意
ミリセチンがマウスの感覚運動機能に及ぼす効果を確認するために、8週齢のICRを(株)コアテック(KOATECH、韓国)から購入し、1週間の予備飼育した後、5匹ずつ2つのグループに分けた。実施例1と同様に実験動物を2つのグループに分けた後、一つ目のグループを陰性対照群に設定して、二つ目のグループは、ミリセチンを50mg/kgの濃度で2週間、毎日1mlを注射器を用いて経口投与した。
3−2.マウスの感覚運動機能の効果測定
ミリセチンが感覚運動機能に及ぼす効果を測定するために、対照群とミリセチン投与群の動物にロータロッド(Panlab&Harvard、Spain)を実施した。ロータロッド実験は、動物の運動協調(exercise adaptation)とバランスを測定するものである(Michel pratte et al.、Behavioural brain research 216:313−320、2011; Medina R.et al.、FEBS Lett.180(1):77−80、1985)。
マウスの尾をつかんでロータロッドに乗せた後、最初のスピードは4rpmから開始して30秒間隔で4rpmずつ上げて5分以内に40rpmまで至るようにしてマウスがロータロッドに留まる時間を測定した。総5回繰り返してロータロッドに最もとどまった時間を結果の値として用いた。上記の実験結果は、実験群と対照群の集団ごとにt検定を実施し、その有意性を検証し、統計学的に有意な差が見えた(** p <0.005)。
実験の結果、図3に示すように、ミリセチンの投与を受けた動物たちがロータロッドに長く滞在することができていることがわかった。したがって、上記の結果から、ミリセチンが運動協調とバランス感覚を増進させる効果があることが分かった。
4−1.各遺伝子の機能
PGC−1α(PeroxisomeProliferator−Activated Receptor γ Coactivator−1α)とNRF−1(Nuclear respiratory factor−1)遺伝子は、ミトコンドリアの生合成と機能を調節する代表的な転写関連遺伝子として、活性化されると、ミトコンドリアの機能と酸化的代謝を調節することが知られている(ChristophHandschin et al.、Endocrine Reviews、27:728−735、2006)。したがって、上記のPGC−1αとNRF−1遺伝子の発現量を測定すると、ミトコンドリア生合成および機能の増進を把握することができる。そこで、本実験例では、ミリセチンを処理する場合、マウスのC 2 C 12 筋管細胞からPGC−1αとNRF−1遺伝子の発現量を観察した。
PPAR−δ(Peroxisome proliferator−activated receptor−δ)遺伝子は、運動をしていない場合でも、運動遂行性を増進するターゲットとして、よく知られている(VihangA. Narkar et al.、Cell、134:405−415、2008) 。したがって、上記のPPAR−δ遺伝子の発現量を測定すると、運動遂行性の増進効能作用剤としての可否を把握することができる。そこで、本実施例では、ミリセチンを処理した場合、マウスのC 2 C 12 筋管細胞でPPAR−δ遺伝子の発現量を観察した。
ミトコンドリアの機能が増進されるということは、エネルギーの消費が増加して、エネルギー効率が良くなるということを意味するので、抗肥満効果を有することができる。したがって、 PGC−1α、NRF−1、PPAR−δ、SIRT−1の発現量を測定すると、抗肥満効果を把握することができる。
マウス筋芽細胞を韓国細胞株銀行から購入して、β−actin、SIRT−1、PGC−1α、NRF−1、PPAR−δ遺伝子に関するプライマーの塩基配列は、それぞれ以下のとおりである。
forward:GGG AAG GTG ACA GCA TTG(配列番号 1)
reverse:ATG AAG TAT TAA GGC GGA AGA TT(配列番号 2)
<SIRT−1>
forward:GTT AGC CTT GTA TTA TGG AGA TGA(配列番号 3)
reverse:TGA GGT AAC TGT TTG AAA(配列番号 4)
<PGC−1α>
forward:AAG GAC TCT GAG AAC ACT TG(配列番号 5)
reverse:CAA CTG ACC CAA ACA CTT TAC(配列番号 6)
<NRF−1>
forward:CCT CAG CCT CCA TCT TCT(配列番号 7)
reverse:GAC CTT ACA ACC AAG CAA CT(配列番号 8)
<PPAR−δ>
forward:CCT CTC TCC CAC TCA CTT(配列番号 9)
reverse:CCA CTT GAA GCA GCA GAT(配列番号 10)
実験の結果、図4a、4b、4c、4dに示すように、ミリセチン10、30、100μMを処理した実験群では、対照群に比べてSIRT−1、PGC−1α、NRF−1、PPAR−δの発現が2〜3倍以上増加した。
本発明者は、ミリセチンの運動機能および感覚機能増進効果を確認するための実験の実行中に、ミリセチンを投与したマウスたちが、体重の減少を示すことを発見して、これを確認するために、ラットを対象にする下記の追加実験を行った。
7週齢のSDラットを(株)コアテック(KOATECH、韓国)から購入して、1週間の予備飼育した後、5匹ずつランダムで2グループに分けた。まず、実験群には、ミリセチン50mg/kgを、対照群には、リン酸緩衝食塩水を5日間投与した。
体重変化の調査は、電子スケール(CAS、中国)を用いて体重を測定した。投与前の各群のラットの体重は平均225gで同じであったが、実験終了の後、対照群の体重は平均285g、ミリセチン投与群の体重は平均275gであった(図5a)。実験の結果、図5aに示すように、ミリセチン投与群のマウスの体重は、リン酸緩衝食塩水投与マウスの体重よりも減少することが観察できた。
餌摂取量の調査は、リン酸緩衝食塩水投与マウスとミリセチン投与群のマウスを行動代謝測定器(Panlab&Harvard、Spain)に毎日餌摂取量を自動的に測定した。餌の摂取量の平均は、グループごとに5匹ずつ2つに分けて、それぞれの平均餌摂取量とした。実験の結果、図5bに示すように、ミリセチン投与マウスの餌摂取量がリン酸緩衝食塩水投与のマウスの餌摂取量よりも減少することを観察することができた。
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 1
gggaaggtga cagcattg 18
<210> 2
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 2
atgaagtatt aaggcggaag att 23
<210> 3
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 3
gttagccttg tattatggag atga 24
<210> 4
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 4
tgaggtaact gtttgaaa 18
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 5
aaggactctg agaacacttg 20
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 6
caactgaccc aaacacttta c 21
<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 7
cctcagcctc catcttct 18
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 8
gaccttacaa ccaagcaact 20
<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 9
cctctctccc actcactt 18
<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> primer
<400> 10
ccacttgaag cagcagat 18
Claims (5)
- ミリセチン(myricetin)またはその薬学的に許容される塩を有効成分として含む運動遂行能力の増強用の薬学的組成物であって、
該運動遂行能力の増強は、筋力強化、バランス感覚の増進、及び/又は運動協調能力(exercise adaptation)の増進である、薬学的組成物。 - ミリセチン(myricetin)またはその薬学的に許容される塩を有効成分として含む運動遂行能力の増強用の食品組成物であって、
該運動遂行能力の増強は、筋力強化、バランス感覚の増進、及び/又は運動協調能力(exercise adaptation)の増進である、食品組成物。 - ミトコンドリアの酸化的な代謝の機能を増加させるための、請求項1または2記載の組成物。
- 前記ミトコンドリアの酸化的な代謝の機能を増加させることが、PGC−1α(Peroxisome Proliferator−Activated Receptor γ Coactivator−1α)、NRF−1(Nuclear respiratory factor−1)、またはPPAR−δ(Peroxisome proliferator−activated receptor−δ)遺伝子の発現を増加させることで遂行される、請求項3記載の組成物。
- 前記ミリセチンはヤマモモの樹皮、シロツメクサの種、蜈蚣草の葉、ツツジの花、ハゼノキ及びクルミで構成される群より選択された原料から抽出されたものであることを特徴とする請求項1〜4のいずれか1項記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0113176 | 2012-10-11 | ||
KR1020120113176A KR101454425B1 (ko) | 2012-10-11 | 2012-10-11 | 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 조성물 |
PCT/KR2013/008372 WO2014058160A1 (ko) | 2012-10-11 | 2013-09-16 | 미리세틴을 유효성분으로 포함하는 운동수행능력 증강용 또는 피로회복용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015535218A JP2015535218A (ja) | 2015-12-10 |
JP6267715B2 true JP6267715B2 (ja) | 2018-01-24 |
Family
ID=50477590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015536673A Active JP6267715B2 (ja) | 2012-10-11 | 2013-09-16 | ミリセチンを有効成分として含む運動遂行能力の増強用または疲労回復用の組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20150283112A1 (ja) |
EP (1) | EP2907517A4 (ja) |
JP (1) | JP6267715B2 (ja) |
KR (1) | KR101454425B1 (ja) |
CN (1) | CN104755089A (ja) |
WO (1) | WO2014058160A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6751709B2 (ja) * | 2015-04-10 | 2020-09-09 | オリザ油化株式会社 | 筋肉細胞におけるエネルギー代謝活性化剤 |
SG11201808981XA (en) * | 2016-04-14 | 2018-11-29 | Benitec Biopharma Ltd | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
WO2019043846A1 (ja) * | 2017-08-30 | 2019-03-07 | 大塚製薬株式会社 | ケンペロール類縁体含有組成物 |
CN107375267A (zh) * | 2017-09-21 | 2017-11-24 | 上海华堇生物技术有限责任公司 | 杨梅素的药物用途 |
JP2019112364A (ja) * | 2017-12-26 | 2019-07-11 | 花王株式会社 | 運動調節機能向上剤 |
WO2019207553A2 (en) | 2018-04-27 | 2019-10-31 | Joslin Diabetes Center, Inc. | Methods and compositions relating to lipokines for treating metabolic disorders |
JP6883364B1 (ja) * | 2020-05-25 | 2021-06-09 | 株式会社東洋新薬 | 経口組成物、筋肉増強用組成物並びに抗肥満用組成物 |
WO2023136399A1 (ko) * | 2022-01-11 | 2023-07-20 | 주식회사 닥터오레고닌 | 진달래 추출물을 유효성분으로 포함하는 항비만 및 근감소 예방 및 치료용 조성물 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1128069A (ja) * | 1997-07-10 | 1999-02-02 | Kyowa Hakko Kogyo Co Ltd | 栄養補給飲食品 |
JP4082823B2 (ja) * | 1999-05-06 | 2008-04-30 | 日本メナード化粧品株式会社 | 光毒性抑制剤 |
JP2011105763A (ja) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar依存的遺伝子転写活性化剤 |
KR100407399B1 (ko) * | 2000-08-22 | 2003-11-28 | 주식회사 뉴로넥스 | 세로토닌 n-아세틸트란스퍼라제의 활성 억제제 |
KR100599496B1 (ko) | 2001-04-23 | 2006-07-12 | 한국생명공학연구원 | 간염 예방 또는 치료용 약학적 조성물 |
KR100526164B1 (ko) | 2005-04-12 | 2005-11-08 | 한국식품연구원 | 운동수행능력 증강용 조성물 |
KR100701272B1 (ko) | 2005-11-25 | 2007-03-29 | 부경대학교 산학협력단 | 백발억제 및 흑모유발 촉진용 조성물 |
KR100692099B1 (ko) | 2006-03-17 | 2007-03-12 | (주)아모레퍼시픽 | 3β-히드록시스테로이드 디하이드로게네이즈 활성 억제용피부화장료 조성물 |
KR20080035378A (ko) * | 2006-10-19 | 2008-04-23 | (주)아모레퍼시픽 | 글루코오스-6-인산 탈수소 효소의 활성 억제용 조성물 |
US20120252887A1 (en) * | 2007-03-19 | 2012-10-04 | Atm Metabolics Lllp | Composition and method for treating diabetes and metabolic disorders |
CN101254186A (zh) * | 2008-04-03 | 2008-09-03 | 沈阳药科大学 | 一种杨梅素的医药新用途 |
KR101121737B1 (ko) | 2009-07-01 | 2012-03-23 | 한동대학교 산학협력단 | 한국산 겨우살이 추출물을 함유한 기능성 흑마늘 토마토 음료 조성물 |
KR101120996B1 (ko) | 2009-10-09 | 2012-03-13 | 대동고려삼 주식회사 | 진세노사이드 Rg3 및 Rg2를 포함하는 운동능력증진 및 피로회복 증진용 조성물 |
WO2012037023A1 (en) * | 2010-09-17 | 2012-03-22 | Stokely-Van Camp, Inc. | Methods of reducing blood lactate concentration |
JP2012171911A (ja) * | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
TWI401030B (zh) * | 2011-02-25 | 2013-07-11 | Scent Blaster Corp | 楊梅乳酪烘焙食品及其製備方法 |
-
2012
- 2012-10-11 KR KR1020120113176A patent/KR101454425B1/ko active IP Right Grant
-
2013
- 2013-09-16 WO PCT/KR2013/008372 patent/WO2014058160A1/ko active Application Filing
- 2013-09-16 US US14/435,424 patent/US20150283112A1/en not_active Abandoned
- 2013-09-16 EP EP13844872.5A patent/EP2907517A4/en not_active Withdrawn
- 2013-09-16 CN CN201380053448.3A patent/CN104755089A/zh active Pending
- 2013-09-16 JP JP2015536673A patent/JP6267715B2/ja active Active
-
2016
- 2016-03-01 US US15/058,065 patent/US9675580B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015535218A (ja) | 2015-12-10 |
KR101454425B1 (ko) | 2014-11-03 |
CN104755089A (zh) | 2015-07-01 |
EP2907517A4 (en) | 2016-04-06 |
EP2907517A1 (en) | 2015-08-19 |
US9675580B2 (en) | 2017-06-13 |
US20150283112A1 (en) | 2015-10-08 |
KR20140048402A (ko) | 2014-04-24 |
US20160175277A1 (en) | 2016-06-23 |
WO2014058160A1 (ko) | 2014-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6267715B2 (ja) | ミリセチンを有効成分として含む運動遂行能力の増強用または疲労回復用の組成物 | |
JP6434228B2 (ja) | 抗疲労剤 | |
WO2011096413A1 (ja) | 運動機能改善剤 | |
CN111228468A (zh) | 一种具有提高运动耐力和帮助运动恢复作用的液体制剂 | |
CN111032037A (zh) | 含山奈酚类似物的组合物 | |
EP1150695B1 (en) | Herbal supplement for increased muscle strength and endurance for athletes | |
KR20020092082A (ko) | 자양강장제 조성물 | |
US20180015134A1 (en) | Composition for increasing exercise performance ability and enhancing physical strength, containing composite extract | |
JPWO2007077995A1 (ja) | 筋肉増量剤 | |
CN104349786B (zh) | 骨骼肌慢肌化剂 | |
WO2021239823A1 (en) | Preventing or treating nitric oxide deficiency related conditions | |
Pekkala et al. | High-intensity interval training and moderate intensity training with exogenous adenosine counteract development of obesity in rats | |
JP6677775B2 (ja) | 筋肉増強剤 | |
EP3119385B1 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
US8603546B2 (en) | Herbal supplement for increased muscle strength and endurance for athletes | |
US8367123B2 (en) | Supplement formula to prevent and deter muscle trauma and method of using same | |
JP2016160216A (ja) | 持久力向上作用又は抗疲労作用を発揮させる方法 | |
JP2008031080A (ja) | 脂質利用促進組成物 | |
McLeay et al. | The effect of a novel keratin protein supplement vs. casein on lean body mass and exercise performance in male athletes | |
Meckes et al. | The effects of carbohydrate-electrolyte drinks on physical and mental performance | |
AU2021398645A1 (en) | Composition for improving muscle flexibility | |
CN112515164A (zh) | 一种增强耐力的液体制剂 | |
JP2014051459A (ja) | 脂質代謝促進剤 | |
WO2014047476A1 (en) | Compositions and methods for improving health in animals | |
WO2013058194A1 (ja) | Srfシグナル活性化剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20151009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160331 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160701 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170223 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170302 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170414 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6267715 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |